Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma - 16/05/15
, Yong Beom Choe, MD, PhD a, c, Kyu Joong Ahn, MD, PhD a, cAbstract |
Background |
BRAF mutations occur in some melanomas. We hypothesized that BRAF mutation rates may differ in melanomas found in Asian compared to white populations.
Objective |
We performed a metaanalysis of BRAF mutations and their associations with the clinicopathologic characteristics of primary melanoma (PM), with a subgroup analysis to compare Asian and white patients with PM.
Methods |
The PubMed, EMBASE, and Cochrane databases were searched up to November 2013. The incidence rates and odds ratios (ORs) of BRAF mutations were calculated using a fixed or random effects model.
Results |
BRAF mutation was associated with younger age (OR = 1.734; P < .001), trunk location (OR = 2.272; P < .001), non–chronically sun damaged skin (OR = 2.833; P < .001), superficial spreading melanoma (OR = 2.081; P < .001), and advanced melanoma stage (OR = 1.551; P = .003). The incidence of BRAF mutations in Asian patients with PM was half that of white patients with PM, but it was linked to the same clinicopathologic characteristics.
Limitations |
Only a small number of studies have been conducted on Asian patients with PMs.
Conclusions |
The BRAF mutation in PM was associated with age, anatomic site based on ultraviolet radiation exposure, histologic subtype, and advanced stage of melanoma. The clinicopathologic associations with BRAF mutations were similar in Asian and white patients with PM.
Le texte complet de cet article est disponible en PDF.Key words : Asians, BRAF mutation, melanoma, metaanalysis, race, systematic review
Abbreviations used : ALM, CI, CSD, I2, LMM, NM, OR, PM, SSM, UV
Plan
| This work was supported by Konkuk University. |
|
| Conflicts of interest: None declared. |
Vol 72 - N° 6
P. 1036 - juin 2015 Retour au numéro
Article précédent
- Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin
- Natalia Jaimes, Ashfaq A. Marghoob, Harold Rabinovitz, Ralph P. Braun, Alan Cameron, Cliff Rosendahl, Greg Canning, Jeffrey Keir
- Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type
- Susan M. Swetter, Frank W. Chen, David D. Kim, Barbara M. Egbert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?